Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001213900-26-027660·AN2 Therapeutics, Inc.
Schedule 13G ownership disclosure
AN2 Therapeutics, Inc.
Common Stock, par value $0.00001 per share · CUSIP: 037326105
Event date: 2026-03-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Vivo Opportunity Fund Holdings, L.P.
Shares: 2,864,346.00 · Class: 8.0%
- Vivo Opportunity, LLC
Shares: 2,864,346.00 · Class: 8.0%
- Vivo Opportunity Cayman Fund, L.P.
Shares: 289,294.00 · Class: 0.8%
- Vivo Opportunity Cayman, LLC
Shares: 289,294.00 · Class: 0.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-26-027660
- Form type
- SCHEDULE 13G
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- Mar 13, 2026
- Reporting period
- Mar 10, 2026
- Description
- Schedule 13G beneficial ownership